DBV Technologies Archives

Infographics 21 Feb 2017

Infographic: The Biggest Biotech Company in Each European Country

We had a look into European biotech and created a map with the biggest biotech companies in each country, according to their market cap. Biotech is one of the biggest employers in Europe, where companies of all sizes strive to bring the most innovative technology to the market. To illustrate the dynamic biotech ecosystem in […]

February 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […]

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Oct 2016

The First Peanut Allergy Therapy might soon hit the Shelves

DBV Technologies announced outstanding Phase IIb results for Viaskin Peanut, which could be the first-ever commercial peanut allergy therapy in the near future. However, competition is stiff. DBV Technologies, the first French Biotech to enter the NASDAQ, aims to be the first to attain approval for a food allergy therapy. The company’s lead pipeline candidate […]

October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Sep 2016

“This Phase I could Pioneer Needle-free Vaccines”, DBV’s CEO

How annoying are needle vaccinations? Very … But the French billion-euro Biotech DBV Technologies wants to bring a paradigm shift via its Anti-allergy Patch platform! I got to chat with the founder & CEO, Pierre-Henri Benhamou, for more insights. DBV’s success continues to amaze me. It’s not only close to solving the global peanut and […]

September 6, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 12 Jul 2016

Which European Biotechs made it to the Billion-Euro Club in 2016?

Europe has a lot of successful Biotech companies, but which of those are worth a billion euros or more? I did a previous version of this article last year and now I explore how these have evolved. Just 9 European Biotech companies (private and public) are worth over one billion right now. Many of these were present last year. For […]

July 12, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 31 May 2016

DBV Technologies: “This is our First and most Significant Partnership signed”

The billion-euro Biotech from Paris DBV Technologies just signed a €100M deal with Nestlé Health Science to develop a new diagnostic test of Milk allergies. This is the first deal of DBV and shows the potential of its technological platform. I had a chat with its COO David Schilansky to find out more… DBV is […]

May 31, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 14 Mar 2016

DBV: “These Additional Results Confirm our Potential of solving the Peanut Allergy problem Worldwide”

DBV Technologies (Paris) was just under the spotlight in Los Angeles at the biggest allergy convention worldwide (2016 AAAAI Annual Meeting). Their Viaskin skin patch could potentially eradicate peanut allergies for patients altogether… Last year, it was the first French Biotech to be listed on the NASDAQ (raising €90M), it then raised €255M (!) in a follow-up round […]

March 14, 2016 - 6 minutesmins - By Philip Hemme

biotech nasdaq stock top biopharma finance 2016

News and Trends 23 Feb 2016

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and brief financial and R&D backgrounds. NASDAQ is the second-largest Stock exchange in the world, based in New York, and the largest for high-tech companies. It seems to be the real test for a European biotech to […]

February 23, 2016 - 6 minutesmins - By Philip Hemme

dbv technologies viaskin peanuts allergy e1457626501488

News and Trends 10 Dec 2015

Peanut Allergies? This Phase III Trial Could Mean an End to Nut-Related Anaphylaxis

Peanut allergy in children can be life-threatening, with safe treatment options available. Now DBV Technologies in Paris has a phase III transdermal patch which desensitizes the patient to peanuts, with fast-track FDA approval. The allergens in peanuts can stimulate an immune response to their presence, which can even result in life-threatening anaphylaxis (here is a […]

December 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Sep 2015

The 9 EU-based Billion-Euro Biotechs you Should (really) Know

Update 22/10/2015: I added Galapagos from Belgium and Basilea from Switzerland, they deserved it … Talking about billon-dollar companies in the US is such a hype. Even the Wall street journal has its own start-up club (which btw is stunning). By looking at it, I wondered which European Biotechs were worth over €1Bn in Europe. […]

September 15, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 19 Aug 2015

Paris is Europe’s biggest Biocluster, but nobody knows it …

Paris is well-known for being the most beautiful city in the world. But did you also know that it concentrates most of the French Biotech industry and is Europe’s biggest biocluster? If not, why didn’t you know? The Eiffel Tower, the Louvre, Notre Dame and so many other monuments makes Paris outstanding and unique. But Paris […]

August 19, 2015 - 5 minutesmins - By Philip Hemme

metamorphosis biopharmceutical innovation bio europe spring 2015

News and Trends 26 Mar 2015

The Metamorphosis of Biopharmaceutical Innovation #BIO-Europe2015

Innovation can occur in many different ways, and biopharmaceutical innovation is no exception. The pipelines of big Pharmas have fewer candidates, R&D costs are skyrocketing, internal research programs tend to shrink and open innovation is raising. This metamorphosis is happening right now and the plenary session of Bio-Europe Spring 2015 focused on this subject. A great opportunity […]

March 26, 2015 - 6 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us